Cargando…

Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018

BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Norma S., Johnson, Anna Satcher, Huang, Ya-Lin A., Kern, Dayle, Fulton, Paul, Smith, Dawn K., Valleroy, Linda A., Hall, H. Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897528/
https://www.ncbi.nlm.nih.gov/pubmed/31805031
http://dx.doi.org/10.15585/mmwr.mm6848e1
_version_ 1783476975208235008
author Harris, Norma S.
Johnson, Anna Satcher
Huang, Ya-Lin A.
Kern, Dayle
Fulton, Paul
Smith, Dawn K.
Valleroy, Linda A.
Hall, H. Irene
author_facet Harris, Norma S.
Johnson, Anna Satcher
Huang, Ya-Lin A.
Kern, Dayle
Fulton, Paul
Smith, Dawn K.
Valleroy, Linda A.
Hall, H. Irene
author_sort Harris, Norma S.
collection PubMed
description BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV infection) and seeks to leverage testing, treatment, and preexposure prophylaxis (PrEP) to reduce new HIV infections in the United States by at least 90% by 2030. Targets to reach this goal include that at least 95% of persons with HIV receive a diagnosis, 95% of persons with diagnosed HIV infection have a suppressed viral load, and 50% of those at increased risk for acquiring HIV are prescribed PrEP. Using surveillance, pharmacy, and other data, CDC determined the current status of these three initiative strategies. METHODS: CDC analyzed HIV surveillance data to estimate annual number of new HIV infections (2013–2017); estimate the percentage of infections that were diagnosed (2017); and determine the percentage of persons with diagnosed HIV infection with viral load suppression (2017). CDC analyzed surveillance, pharmacy, and other data to estimate PrEP coverage, reported as a percentage and calculated as the number of persons who were prescribed PrEP divided by the estimated number of persons with indications for PrEP. RESULTS: The number of new HIV infections remained stable from 2013 (38,500) to 2017 (37,500) (p = 0.448). In 2017, an estimated 85.8% of infections were diagnosed. Among 854,206 persons with diagnosed HIV infection in 42 jurisdictions with complete reporting of laboratory data, 62.7% had a suppressed viral load. Among an estimated 1.2 million persons with indications for use of PrEP, 18.1% had been prescribed PrEP in 2018. CONCLUSION: Accelerated efforts to diagnose, treat, and prevent HIV infection are needed to achieve the U.S. goal of at least 90% reduction in the number of new HIV infections by 2030.
format Online
Article
Text
id pubmed-6897528
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-68975282019-12-12 Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 Harris, Norma S. Johnson, Anna Satcher Huang, Ya-Lin A. Kern, Dayle Fulton, Paul Smith, Dawn K. Valleroy, Linda A. Hall, H. Irene MMWR Morb Mortal Wkly Rep Vital Signs BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV infection) and seeks to leverage testing, treatment, and preexposure prophylaxis (PrEP) to reduce new HIV infections in the United States by at least 90% by 2030. Targets to reach this goal include that at least 95% of persons with HIV receive a diagnosis, 95% of persons with diagnosed HIV infection have a suppressed viral load, and 50% of those at increased risk for acquiring HIV are prescribed PrEP. Using surveillance, pharmacy, and other data, CDC determined the current status of these three initiative strategies. METHODS: CDC analyzed HIV surveillance data to estimate annual number of new HIV infections (2013–2017); estimate the percentage of infections that were diagnosed (2017); and determine the percentage of persons with diagnosed HIV infection with viral load suppression (2017). CDC analyzed surveillance, pharmacy, and other data to estimate PrEP coverage, reported as a percentage and calculated as the number of persons who were prescribed PrEP divided by the estimated number of persons with indications for PrEP. RESULTS: The number of new HIV infections remained stable from 2013 (38,500) to 2017 (37,500) (p = 0.448). In 2017, an estimated 85.8% of infections were diagnosed. Among 854,206 persons with diagnosed HIV infection in 42 jurisdictions with complete reporting of laboratory data, 62.7% had a suppressed viral load. Among an estimated 1.2 million persons with indications for use of PrEP, 18.1% had been prescribed PrEP in 2018. CONCLUSION: Accelerated efforts to diagnose, treat, and prevent HIV infection are needed to achieve the U.S. goal of at least 90% reduction in the number of new HIV infections by 2030. Centers for Disease Control and Prevention 2019-12-06 /pmc/articles/PMC6897528/ /pubmed/31805031 http://dx.doi.org/10.15585/mmwr.mm6848e1 Text en https://creativecommons.org/licenses/by/3.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
spellingShingle Vital Signs
Harris, Norma S.
Johnson, Anna Satcher
Huang, Ya-Lin A.
Kern, Dayle
Fulton, Paul
Smith, Dawn K.
Valleroy, Linda A.
Hall, H. Irene
Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
title Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
title_full Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
title_fullStr Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
title_full_unstemmed Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
title_short Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
title_sort vital signs: status of human immunodeficiency virus testing, viral suppression, and hiv preexposure prophylaxis — united states, 2013–2018
topic Vital Signs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897528/
https://www.ncbi.nlm.nih.gov/pubmed/31805031
http://dx.doi.org/10.15585/mmwr.mm6848e1
work_keys_str_mv AT harrisnormas vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT johnsonannasatcher vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT huangyalina vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT kerndayle vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT fultonpaul vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT smithdawnk vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT valleroylindaa vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018
AT hallhirene vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018